WO2010027279A3 - Compositions and methods for the treatment and prevention of neoplastic disorders - Google Patents

Compositions and methods for the treatment and prevention of neoplastic disorders Download PDF

Info

Publication number
WO2010027279A3
WO2010027279A3 PCT/NZ2009/000183 NZ2009000183W WO2010027279A3 WO 2010027279 A3 WO2010027279 A3 WO 2010027279A3 NZ 2009000183 W NZ2009000183 W NZ 2009000183W WO 2010027279 A3 WO2010027279 A3 WO 2010027279A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
prevention
treatment
methods
neoplastic disorders
Prior art date
Application number
PCT/NZ2009/000183
Other languages
French (fr)
Other versions
WO2010027279A2 (en
Inventor
Glen Reid
Original Assignee
Genesis Research And Development Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Research And Development Corporation Limited filed Critical Genesis Research And Development Corporation Limited
Publication of WO2010027279A2 publication Critical patent/WO2010027279A2/en
Publication of WO2010027279A3 publication Critical patent/WO2010027279A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/04—Oxidoreductases acting on CH or CH2 groups (1.17) with a disulfide as acceptor (1.17.3)
    • C12Y117/04001—Ribonucleoside-diphosphate reductase (1.17.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Compositions for the treatment and/or prevention of cancer in a mammal by means of RNA interference are provided, together with methods for the use of such compositions. The compositions comprise a small interfering nucleic acid molecule (siNA) that suppresses expression of a target gene that is involved in the biosynthesis of nucleotides within a tumor cell.
PCT/NZ2009/000183 2008-09-04 2009-09-03 Compositions and methods for the treatment and prevention of neoplastic disorders WO2010027279A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9433708P 2008-09-04 2008-09-04
US61/094,337 2008-09-04

Publications (2)

Publication Number Publication Date
WO2010027279A2 WO2010027279A2 (en) 2010-03-11
WO2010027279A3 true WO2010027279A3 (en) 2010-04-29

Family

ID=41797694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2009/000183 WO2010027279A2 (en) 2008-09-04 2009-09-03 Compositions and methods for the treatment and prevention of neoplastic disorders

Country Status (1)

Country Link
WO (1) WO2010027279A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005769A2 (en) * 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
WO2004104197A1 (en) * 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2005116204A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2008026946A2 (en) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005769A2 (en) * 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2004104197A1 (en) * 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2005116204A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2008026946A2 (en) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders

Also Published As

Publication number Publication date
WO2010027279A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2008026946A3 (en) Compositions and methods for the treatment and prevention of neoplastic disorders
WO2008150897A3 (en) Reduction of off-target rna interference toxicity
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2008103763A3 (en) Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
WO2007044727A3 (en) Pkr activation via hybridization chain reaction
WO2005034845A8 (en) Compositions and methods for treatment of cancer
WO2006135684A3 (en) Methods and kits for sense rna synthesis
WO2011072246A3 (en) Tal effector-mediated dna modification
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2007087451A3 (en) Compositions and methods for enhancing discriminatory rna interference
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2008036825A3 (en) Duplex oligonucleotide complexes and methods for gene silencing by rna interference
WO2007139723A8 (en) Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
EP2379597B8 (en) Egfr-homing double-stranded rna vector for systemic cancer treatment
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
BRPI0810418A8 (en) target binding members, isolated nucleic acid, expression vector, host cell, composition, methods for producing a target binding member, for treating or preventing asthma, and for producing an antibody against il-25.
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09811757

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09811757

Country of ref document: EP

Kind code of ref document: A2